Arvinas ARVN Unrecognized compensation cost related to non-vested awards

Unrecognized compensation cost related to non-vested awards at other companies

Relmada Therapeutics, Inc.RLMD

——

Revenue$15.6M-91.7%

Operating income-$63.8M-189%

Net income-$57.6M-169%

EPS (diluted)-$0.90-179%

Cash & equivalents$87.3M+7.8%

Total debt$8.6M-19.6%

Total equity$386.8M-41.4%

Total assets$647.5M-35.3%

Operating cash flow-$69.2M+22.2%

CapEx$1.3M+225%

Free cash flow-$70.5M+21.1%

Market cap$518.11M-4.6%

Enterprise value$439.41M-7.1%

P/S5.8×+4.5×

Operating margin-283.8%-310pp

Net margin-247.5%-260pp

FCF margin-287.4%—

Return on equity-42.3%-53.5pp

Debt / equity0×0.0×

Current ratio5.4×+0.9×

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Arvinas's unrecognized compensation cost related to non-vested awards?: Arvinas (ARVN) reported unrecognized compensation cost related to non-vested awards of $45.8M in Q1 2026.
How has Arvinas's unrecognized compensation cost related to non-vested awards changed year-over-year?: Arvinas's unrecognized compensation cost related to non-vested awards decreased by 37.8% year-over-year, from $73.6M to $45.8M.